Literature DB >> 12134369

Positron emission tomography in thyroid cancer management.

Steven M Larson1, Richard Robbins.   

Abstract

Selected patients with thyroid cancer can benefit from the use of PET imaging with FDG or with I-124. The PET scan impacts on management by providing (1) more accurate information about staging of patients in terms of extent of tumor for better treatment planning, especially in patients who do not concentration radioactive I-131; (2) the relationship of tumor involvement to vital structures, especially in the neck and central nervous system; and (3) prognostic information (an SUV > 10 and extensive PET + disease connotes a poor prognosis in advanced patients). In the occasional patient, surgically respectable disease has been identified on PET with the result that the patient has been rendered no evident disease with treatment. PET has also been used in the follow-up of patients who have been treated for thyroid cancer, to assess response. PET may also be useful for lesion specific dosimetry, with I-124. The combination of PET and CT in the same gantry facilitates localization of thyroid cancer PET scan abnormalities in relationship to critical organs and structures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134369     DOI: 10.1016/s0037-198x(02)80035-9

Source DB:  PubMed          Journal:  Semin Roentgenol        ISSN: 0037-198X            Impact factor:   0.800


  9 in total

1.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

2.  Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.

Authors:  Heejin Kim; Kyung Jin Na; Jae Hyuk Choi; Byeong-Cheol Ahn; Dongbin Ahn; Jin Ho Sohn
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

3.  Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre.

Authors:  Elaine Lam; Scott S Strugnell; Chris Bajdik; Daniel Holmes; Sam M Wiseman
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

4.  Challenging cases in thyroid cancer: a multidisciplinary approach.

Authors:  Michael Tuttle; Richard Robbins; Steven M Larson; H William Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

Review 5.  Molecular imaging in thyroid cancer.

Authors:  T F Heston; R L Wahl
Journal:  Cancer Imaging       Date:  2010-01-20       Impact factor: 3.909

6.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

7.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

8.  Clinical use of PET/CT in thyroid cancer diagnosis and management.

Authors:  Fx Sundram
Journal:  Biomed Imaging Interv J       Date:  2006-10-01

9.  Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer.

Authors:  Steven M Larson; Joseph R Osborne; Ravinder K Grewal; R Michael Tuttle
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.